UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Lung cancer (Amsterdam, Netherlands), 2012-05, Vol.76 (2), p.177-182

2012

Volltextzugriff (PDF)

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Lung cancer (Amsterdam, Netherlands), 2011-08, Vol.73 (2), p.195-202

2011

Volltextzugriff (PDF)

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-11, Vol.86 (2), p.207-212

2014

Volltextzugriff (PDF)

Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors

Bioorganic & medicinal chemistry letters, 2012-10, Vol.22 (19), p.6301-6305

2012

Volltextzugriff (PDF)

Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-11, Vol.877 (30), p.3781-3786

2009

Volltextzugriff (PDF)

Efficacy of icotinib in advanced lung squamous cell carcinoma

Cancer medicine (Malden, MA), 2018-09, Vol.7 (9), p.4456-4466

2018

Volltextzugriff (PDF)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

PloS one, 2015-11, Vol.10 (11), p.e0142500-e0142500

2015

Volltextzugriff (PDF)

Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

Cancer chemotherapy and pharmacology, 2014-04, Vol.73 (4), p.721-727

2014

Volltextzugriff (PDF)

P492: SAFETY AND EFFICACY OF LP‐108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e2546261-n/a

2023

Volltextzugriff (PDF)

P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP‐108, A NOVEL AND SELECTIVE BCL‐2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

HemaSphere, 2023-08, Vol.7 (S3), p.e324590c-n/a

2023

Volltextzugriff (PDF)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Oncotarget, 2017-02, Vol.8 (6), p.9996-10006

2017

Volltextzugriff (PDF)

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Journal of thoracic oncology, 2016-06, Vol.11 (6), p.910-917

2016

Volltextzugriff (PDF)

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7071-TPS7071

2022

Volltextzugriff (PDF)

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21108-e21108

2018

Volltextzugriff (PDF)

Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017-11, Vol.1068-1069, p.33-40

2017

Volltextzugriff (PDF)

Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

Future oncology (London, England), 2015-02, Vol.11 (3), p.385-397

2015

Volltextzugriff (PDF)

Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.262-267

2015

Volltextzugriff (PDF)

BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus

Pharmacological research, 2017-08, Vol.122, p.130-139

2017

Volltextzugriff (PDF)

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR -mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study

Lung cancer (Amsterdam, Netherlands), 2016-06, Vol.96, p.93-100

2016

Volltextzugriff (PDF)

Icotinib as first-line or maintenance therapy in patients with advanced lung adenocarcinoma with positive EGFR mutation and the influence of cytokines shift on survival

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20658-e20658

2017

Volltextzugriff (PDF)

eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS8578-TPS8578

2017

Volltextzugriff (PDF)

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS9115-TPS9115

2018

Volltextzugriff (PDF)

Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry

Rapid communications in mass spectrometry, 2011-08, Vol.25 (15), p.2131-2140

2011

Volltextzugriff (PDF)

Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models

Biomedicine & pharmacotherapy, 2018-02, Vol.98, p.399-405

2018

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(19)
Male
(15)
Oncology
(14)
Female
(12)
Icotinib
(12)
Lung Neoplasms - Drug Therapy
(10)
Middle Aged
(10)
Aged
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Crown Ethers - Therapeutic Use
(8)
Quinazolines - Therapeutic Use
(8)
Receptor, Epidermal Growth Factor - Genetics
(8)
Treatment Outcome
(8)
Adult
(7)
Crown Ethers - Adverse Effects
(7)
Hematology, Oncology And Palliative Medicine
(7)
Mutation
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)

Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors

Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry

Efficacy of icotinib in advanced lung squamous cell carcinoma

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

P492: SAFETY AND EFFICACY OF LP‐108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA

P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP‐108, A NOVEL AND SELECTIVE BCL‐2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study

Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients

Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer

BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR -mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study

Icotinib as first-line or maintenance therapy in patients with advanced lung adenocarcinoma with positive EGFR mutation and the influence of cytokines shift on survival

eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients

Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry

Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models

Suchergebnisse filtern